Background: Erectile dysfunction and low testosterone levels frequently occur together.
rectile dysfunction (ED), the consistent inability over at least 3 months to achieve or maintain penile erection sufficient for satisfactory sexual performance, affects nearly 1 in 3 men older than 50 years (1-3). Because of its high prevalence, profound effect on quality of life, and association with diabetes mellitus and cardiovascular disease, the medical and socioeconomic consequences of ED are substantial (4, 5) . Selective phosphodiesterase type 5 (PDE5) inhibitors have emerged as first-line therapy for ED because of their efficacy and relative safety (6) .
Testosterone is recognized as an important regulator of sexual desire, spontaneous sexual thoughts, motivation, attentiveness to erotic stimuli, and sexual activity in men (7) (8) (9) . In animal models, testosterone has been reported to regulate penile nitric oxide synthase, corporeal venous occlusion, penile blood flow, and corpus cavernosum smooth muscle mass, leading to speculation that, in men, normal testosterone concentrations may be necessary to achieve an optimum response to PDE5 inhibitors (10 -16) . Because ED and low testosterone levels often coexist, several expert panels and professional societies have suggested that men with ED should have their testosterone levels checked and that testosterone supplementation should be considered if levels are low (1, (17) (18) (19) (20) . Combining testosterone and a PDE5 inhibitor has become increasingly common in the treatment of men with ED and low testosterone levels (21) . However, an expert panel of the American College of Physicians found the evidence to be insufficient to recommend either routine measurement of serum testosterone or testosterone therapy for men with ED (6, 22) .
The primary objective of this trial was to determine whether, in comparison with placebo, testosterone replacement in middle-aged and older men with ED and low testosterone levels improves the erectile response to an optimized dose of sildenafil citrate, which is a PDE5 inhibitor. The secondary aim was to determine whether combined administration of testosterone plus an optimized dose of sildenafil is more effective than placebo plus sildenafil in improving other aspects of sexual function (sexual desire and ejaculatory and orgasmic function); the frequency, quality, and satisfaction with intercourse; ED-related quality of life; well-being; affectivity balance; and partner intimacy.
METHODS

Study Design
This randomized, placebo-controlled, double-blind, parallel-group trial in men with ED and low testosterone levels was approved by the Institutional Review Board of the Boston University Medical Campus. Each participant provided written informed consent. Study recruitment started in September 2004, and the last participant completed the study in May 2010. A data and safety monitoring board reviewed adverse events semiannually.
The trial consisted of a screening phase, a sildenafil dose-optimization phase, and an intervention phase, in which an optimized dose of sildenafil was administered in combination with either testosterone or placebo gel (Figure 1 ).
Participants
Participants were recruited through newspaper advertisements and from the Center for Sexual Medicine and Center for Endocrinology at Boston Medical Center. Eligibility criteria included age between 40 and 70 years, ED as indicated by a score of 25 or less on the erectile function domain (EFD) of the International Index of Erectile Function (IIEF), having a sexual partner, and a serum total testosterone level less than 11.45 nmol/L (Ͻ330 ng/dL) or a free testosterone level less than 173.35 pmol/L (Ͻ50 pg/mL)-both well below the lower limits of normal established in healthy men (12. 08 nmol/L [348 ng/dL] and 242.69 pmol/L [70 pg/mL], respectively [23] ).
Men were excluded if they had prostate or breast cancer, structural abnormalities of the penis, lower urinary tract symptom scores of 21 or greater, untreated sleep apnea, major psychiatric diseases, hematocrit greater than 0.50, creatinine levels greater than 176.8 mol/L (Ͼ2 mg/ dL), prostate-specific antigen (PSA) levels greater than 4 g/L, hemoglobin A 1c levels of 8.5% or greater, blood pressure greater than 160/100 mm Hg, myocardial infarctions or strokes in the previous 6 months, or uncontrolled heart failure. Men using androgens, antiandrogens, and nitrates were excluded. Participants using PDE5 inhibitors were asked to stop therapy for 1 month before enrollment.
Optimization of Sildenafil Dose
During the 3-to 7-week open-label run-in phase, sildenafil-naive participants began 50-mg sildenafil therapy as needed for sexual activity but no more than once daily. Men receiving ␣-adrenergic blockers began 25-mg sildenafil therapy. Men who had previously used 100-mg sildenafil initiated this dose. Response to sildenafil was evaluated 3 weeks later using a structured questionnaire, and participants who reported satisfactory erections without adverse effects advanced to randomization. Participants reporting dissatisfaction with erectile function had their sildenafil doses increased to 50 or 100 mg, were reevaluated 4 weeks later, and then advanced to randomization. Participants were instructed to continue this optimized dose throughout the study.
Randomization
Participants were randomly assigned without stratification in a concealed 1:1 allocation to either testosterone or placebo gel by using permuted blocks with a block size of 4. A statistician generated a randomization sequence, which was given to the investigational drug pharmacy for implementation. Pharmacists assigned participants to a randomization number and testosterone or placebo gel and recorded allocation in a concealed table.
Testosterone Dose Adjustment
Participants were randomly assigned to receive either 10 g of 1% transdermal testosterone gel (Testim, Auxilium Pharmaceuticals, Malvern, Pennsylvania) or placebo gel. This dose of testosterone gel increases testosterone concentrations into mid-normal range in men with hypogonadism (24, 25) . Participants were instructed to apply 3 tubes of gel daily to facilitate dosing of testosterone at 5, 10, or 15 g daily while maintaining blinding. Men in the testosterone group initially received 2 active tubes, each containing 5 g of testosterone gel, and 1 tube of placebo gel, whereas men in the placebo group received 3 tubes of placebo gel. Two weeks after randomization, testosterone levels were measured and reviewed by an unblinded physician, who increased the daily testosterone dose to 15 g (3 active tubes) if the mean testosterone level was less than 17.35 nmol/L (Ͻ500 ng/dL) or decreased it to 5 g (1 active tube plus 2 tubes of placebo gel) if the mean testosterone level was greater than 34.7 nmol/L (Ͼ1000 ng/dL).
Blinding
The investigating staff and participants were blinded to intervention allocation. Testosterone and placebo gels
Context
Some physicians prescribe sildenafil plus testosterone to treat erectile dysfunction in men who have low testosterone levels.
Contribution
In this study of men with erectile dysfunction and low testosterone levels, sildenafil alone improved erectile function as much as sildenafil plus testosterone.
Caution
This study did not examine whether testosterone can improve erectile function without sildenafil.
Implication
Physicians should prescribe sildenafil alone to treat erectile dysfunction in men who have low testosterone levels.
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Original Research Effect of Testosterone on Response to Sildenafil were packaged in identical tubes, and participants were prescribed 3 tubes of gel daily to maintain blinding. Investigators and study staff did not have access to the randomization table, which was sequestered by the pharmacist.
Outcomes
The primary outcome was change in EFD score of the IIEF from randomization to the end of the 14-week intervention phase. The IIEF is a validated, 15-question, multidimensional measure of erectile function that has been widely used in ED trials (26, 27) . Other domains of the IIEF and composite scores (sum of all domains) were computed as secondary outcomes. We used Sexual Encounter Profile (SEP) diaries to assess frequency of sexual activity, sildenafil use, vaginal penetration, completion of intercourse with ejaculation, and overall satisfaction with sexual encounters (15, 28) . Sexual desire, sexual satisfaction, and ejaculatory function were assessed by using the Male Sexual Health Questionnaire (MSHQ), which provides a more comprehensive assessment of these domains than the IIEF (29) . Composite MSHQ scores were calculated as the sum of the ejaculation and satisfaction domains. A global assessment question ("Do you feel that your participation in this study has led to an improvement in your sexual function?") was used to determine participants' perception of overall improvement.
The effect of ED on quality of life was assessed using the Quality of Life Specific to Male Erection Difficulties scale (30) . The Cancer Rehabilitation Evaluation System- † Percentages may not sum to 100 due to rounding. ‡ Percentages are based on the number of participants who responded rather than the total number of participants in the group.
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Short Form marital interaction scale was used to determine intimacy and partner interaction (31, 32) . Well-being, energy, and vitality were assessed using the Psychological General Well-Being Index, and affectivity balance was assessed using the Derogatis Affects Balance Scale (33, 34) .
Schedule of Assessments
The IIEF was administered at screening; at baseline; at the end of the sildenafil dose-optimization period; and during weeks 8, 11, and 14 after randomization. The MSHQ, SEP diaries, Psychological General Well-Being Index, Derogatis Affects Balance Scale, marital interaction scale, and quality-of-life scale were administered at baseline, at the end of the sildenafil dose-optimization period, and during weeks 8 and 14. Adverse events were ascertained at each visit. Hemoglobin A 1c levels, hematocrit, complete metabolic panels, PSA levels, and lower urinary tract symptoms were checked and prostate examinations were done periodically.
Hormone Assays
Total testosterone levels were measured between 7:30 and 10:00 a.m. using a liquid chromatography-tandem mass spectrometry assay certified by the Centers for Disease Control and Prevention's Hormone Standardization Program (23, 35) . The sensitivity was 0.07 nmol/L (2 ng/ dL). Interassay coefficient of variation was 7.9% at 1.69 nmol/L (48.6 ng/dL), 7.7% at 8.36 nmol/L (241 ng/dL), and 4.4% at 18.46 nmol/L (532 ng/dL). The bias in quality control samples provided by the Centers for Disease Control and Prevention between 3.47 nmol/L (100 ng/dL) and 34.7 (1000 ng/dL) was less than 6.2%. Free testosterone levels were calculated from total testosterone at screening and equilibrium dialysis at randomization and at trial end (36, 37) .
Sample Size Determination
We hypothesized that the addition of placebo gel to sildenafil would improve the EFD score by 2 points, whereas the addition of testosterone gel would increase the EFD score 6 points higher than that seen using sildenafil alone. We assumed that the SD of postrandomization change on this measure would be approximately 6 points. A sample size of 60 evaluable men in each group would provide approximately 95% power to detect a clinically meaningful 4-point difference in EFD score between placebo and testosterone groups in an unadjusted linear regression model (38, 39) . In anticipation of an attrition rate less than 15%, the sample size was increased to 70 in each group.
Statistical Analysis
The prespecified primary analysis computed changes in EFD and other continuous outcomes from randomization to 14 weeks after randomization. Unadjusted mean changes were compared across treatment groups by linear regression. Logistic regression was used to assess the association between the intervention and responses to the global assessment question. For these models, values for missing data were obtained by using multiple imputation by chained equations (40). For the EFD and global assessment question, we obtained 25 imputations with linear and logistic models, respectively, using age, race, body mass index, comorbid conditions, and serum testosterone levels as covariates. The combined point and variance estimates for testosterone effects were then computed. The statistical significance of treatment effects on continuous outcomes in the linear models was determined by using Wald-type test statistics (41) , whereas a likelihood ratio test was used for the logistic models (42) . Sensitivity analyses restricted to participants completing 14 weeks of the intervention (that is, not using imputation) were done using conventional linear and logistic regression. Subsequently, exploratory models were used to assess whether estimates were affected by the inclusion of the covariates already described as either potential confounders or effect modifiers and whether results differed within certain sample subgroups (for example, among participants with diabetes or testosterone levels less than 8.68 nmol/L [Ͻ250 ng/dL]). These exploratory subgroup models were not prespecified.
After the analyses of data at randomization and 14 weeks, secondary analyses of data at all time points were conducted by using generalized estimating equations (43) with autoregressive correlation structures and robust ("sandwich") variance estimation, using only treatment as a control factor. For these models, between-group differences in postrandomization changes in outcomes were generated using treatment contrasts and statistical significance was determined using robust Wald-type tests.
Finally, the number and proportion of participants in each group reporting adverse events were compared using Fisher exact tests. All point estimates were accompanied by 95% CIs and all hypothesis tests were 2-sided, with results considered statistically significant if the null hypotheses could be rejected at the 0.05 level. Statistical analyses were done in SAS, version 9.3 (SAS Institute, Cary, North Carolina), and R, version 2.14.2 (R Foundation for Statistical Computing, Vienna, Austria) (44).
Role of the Funding Source
This study was funded by the National Institute of Child Health and Human Development. The Boston University Clinical and Translational Science Institute provided clinic space, and the Boston Claude D. Pepper Older Americans Independence Center supported some research staff. Auxilium Pharmaceuticals provided testosterone and placebo gel, and Pfizer (New York, New York) provided sildenafil citrate. The funding source had no role in trial design, data analyses, manuscript preparation, or the decision to submit the manuscript for publication. 
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The study included assessments during week Ϫ13, a sildenafil dose-optimization phase (weeks Ϫ7 to 0) (shaded areas), and a 14-week postrandomization period. The day of randomization was designated as day 0. Higher IIEF scores reflect better erectile function. IIEF ϭ International Index of Erectile Function.
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RESULTS
Participants
We screened 1379 men and 152 entered the sildenafil run-in period, 140 of whom were randomly assigned and included in the primary analysis (Figure 1) .
The baseline characteristics in the 2 groups were similar ( Table 1) . In each group, 68 (97%) were heterosexual, 1 (1%) was homosexual, and 1 (1%) was bisexual. Nearly one half had hypertension or cardiovascular disease, and more than one half were obese.
Sildenafil Administration
At the end of the optimization phase, 53 (76%), 16 (23%), and 1 (1%) men in the testosterone group and 53 (76%), 17 (24%), and 0 (0%) men in the placebo group were receiving 100, 50, and 25 mg of sildenafil, respectively. Mean sildenafil use was 2.7 tablets per week (SD, 1.4) and 2.6 tablets per week (SD, 0.9) after dose optimization in the testosterone and placebo groups, respectively, and remained unchanged at week 14.
Adherence
Adherence, assessed by counting used gel tubes, was 90% for testosterone and 89% for placebo.
Testosterone Levels
Total testosterone levels averaged 8.61 nmol/L (248 ng/dL) and 8.81 nmol/L (254 ng/dL) at baseline in the testosterone and placebo groups, respectively ( Table 1) . Total testosterone levels increased to 12.63 nmol/L (364 ng/dL) and 12.04 nmol/L (347 ng/dL) at the end of the sildenafil dose-optimization phase in the testosterone and placebo groups, respectively (Appendix Figure 1 , available at www.annals.org). Of the 70 men randomly assigned to testosterone, 15 (21%) had their doses adjusted to 5 g of testosterone daily, whereas 9 (13%) required a dose increase to 15 g of testosterone daily. On-treatment mean 
Testosterone Placebo
The day of randomization was designated as day 0. The shaded areas represent the sildenafil dose-optimization phase (weeks Ϫ7 to 0). Higher QOL-MED, PGWBI, and DABS scores reflect better quality of life, vitality, and affect, respectively, than lower scores. Lower CARES-SF scores correspond with improved marital interaction. Appendix testosterone levels further increased to 22.52 nmol/L (649 ng/dL) in the testosterone group but remained unchanged in the placebo group (Appendix Figure 1 and Appendix Table 1 , available at www.annals.org).
Changes in Sexual Function
Sildenafil administration alone was associated with substantial increases in all domains of the IIEF, including the EFD in both groups. Mean EFD score increased by 7.7 (95% CI, 6.5 to 8.8) for all participants, from 12.1 to 19.8 (Figure 2) . The primary analysis indicated that 14-week change in EFD score after randomization (primary outcome) did not differ significantly between the testosterone and placebo groups (difference between mean changes, 2.2 [CI, Ϫ0.8 to 5.1]; P ϭ 0.150) (Figure 2) . Postrandomization changes in other domains of the IIEF, including sexual desire, intercourse satisfaction, overall satisfaction, and orgasmic function, as well as composite IIEF score, did not differ between the groups (Figure 2) . Supporting longitudinal analysis by generalized estimating equations demonstrated no significant difference between testosterone and placebo for the EFD or other measures of sexual function at 14 weeks (Appendix Table 2 , available at www.annals.org).
During the sildenafil run-in period, the frequency of sexual encounter attempts, vaginal penetration, ejaculation, overall satisfaction with sexual encounters, and percentage of successful encounters improved similarly in both groups (Appendix Figure 2 , available at www.annals.org). After randomization, change in SEP outcomes, including frequency of sexual encounters and percentage of successful sexual intercourse, did not significantly differ between groups (Appendix Figure 2 and Appendix Table 2 ). The results of sexual desire and ejaculatory function assessment using the MSHQ were similar to those obtained by using the IIEF. Sildenafil administration alone was associated with improvements in these MSHQ domains; however, changes in MSHQ domain scores and composite score after randomization did not differ significantly between the groups (Appendix Figure 3, available at www.annals.org) .
Erectile dysfunction-related quality of life improved with sildenafil administration alone in both groups, but change in quality of life after randomization did not differ between groups (Figure 3 and Appendix Table 1 ). Measures of vitality, positive affects ratio, and marital intimacy did not change in either group (Figure 3 and Appendix Table 1 ).
The proportion of participants reporting improvement in global assessment of sexual function did not differ significantly between groups (85% for testosterone and 71% for placebo; P ϭ 0.136).
Sensitivity Analysis
Per-protocol analysis of men who completed 14 weeks of the intervention confirmed the results of primary analysis and did not reveal a significant difference in changes in the EFD score (difference, 1.1 [CI, Ϫ1.2 to 3.5]; P ϭ 0.33; 112 participants). The effect of testosterone on erectile function among participants with testosterone levels less than 8.68 nmol/L (Ͻ250 ng/dL) or 8.68 nmol/L or greater (Ն250 ng/dL) was similar ( Table 2) . Moreover, the effect of testosterone on erectile function did not differ by age (Ͻ55.5 vs. Ն55.5 years), body mass index (Ͻ30 vs. Ն30 kg/m 2 ), and response to sildenafil alone during the run-in period (change in EFD Ͻ4 vs. Ն4), which supported absence of effect modification by these factors ( Table 2) .
Adverse Events
The frequency of adverse events did not differ between the 2 groups ( Table 3) . Hematocrit increased significantly more in the testosterone group than in the placebo group (P ϭ 0.011) (Appendix Figure 1 and Appendix Table 1 ). Two participants in the testosterone group and none in the placebo group developed hematocrit greater than 0.54. Four participants in the testosterone group but none in the placebo group had PSA levels greater than 4 g/L; change in PSA levels did not differ between groups.
DISCUSSION
In men with ED who had low testosterone levels, the addition of a replacement dose of testosterone to an optimized dose of sildenafil was not associated with greater improvement in erectile function than that associated with addition of placebo gel. Sildenafil plus testosterone was not superior to sildenafil plus placebo in improving any domain of sexual function, frequency of total or satisfactory Original Research Effect of Testosterone on Response to Sildenafil sexual encounters, vitality, ED-related quality of life, or marital intimacy. Thus, these data do not support the routine addition of testosterone to a PDE5 inhibitor therapy to improve erectile response in men with ED and low testosterone levels. This trial had many attributes of good trial design: concealed randomization, a placebo control, blinding, and parallel-group design. Randomization effectively generated 2 intervention groups that were similar in baseline characteristics. Considerations of effect size and statistical power guided the sample size. Testosterone dose was adjusted and was effective in increasing testosterone levels into the target range. Sildenafil dose was optimized in an initial run-in period and remained constant throughout the intervention. Sildenafil use and dose were similar in the 2 groups. Mean total and free testosterone levels, measured by using state-of-the-art methods, at baseline were well below the lower limits of normal established in community-based samples and validated against outcomes in epidemiologic studies (23) . Rates of loss to follow-up were similar or lower than those reported in other testosterone trials (14, 15) .
The internal consistency of data from this trial is reassuring. The baseline characteristics of participants, including the prevalence of diabetes and hypertension, were typical of men with ED (4). As expected, the administration of sildenafil alone in the run-in phase was associated with a marked and sustained increase in erectile function and other domains of the IIEF similar to that reported in previous trials (27, 45). Similar improvements occurred during the sildenafil run-in period in men who were subsequently randomly assigned to the testosterone group and those assigned to the placebo group. The findings from the IIEF were confirmed by the results obtained using the MSHQ and SEP diaries. Stratification by sildenafil response, baseline testosterone level, and age did not reveal a clinically meaningful difference of at least 4 in EFD scores after the intervention (39) . Similarly, the primary analysis was corroborated by the per-protocol analyses of participants who completed the intervention phase.
The failure of testosterone to improve erectile response to sildenafil may seem surprising in light of preclinical studies suggesting that testosterone plays an important role in penile erection, including production of nitric oxide, enhancement of penile blood flow and venous occlusion, and maintenance of penile smooth muscle mass (11, 12, 16, 46) . Testosterone trials in men with hypogonadism have reported improvements in sexual activity scores (24, 47) . However, the few randomized, placebo-controlled trials that have investigated the effect of adding testosterone to PDE5 inhibitor therapy on ED have yielded inconsistent results. As reviewed in a meta-analysis, some inconsistencies may be related to the inclusion of men whose testosterone levels were in the normal range, failure to optimize sildenafil dose before addition of testosterone, and small size of some trials (22) . Another randomized trial of men with serum testosterone levels of 13.88 nmol/L (400 ng/dL) or less did not find significant differences in the EFD of the IIEF between men receiving tadalafil and either testosterone or placebo gel, although in a post hoc subanalysis, men with baseline testosterone levels less than 10.41 nmol/L (Ͻ300 ng/dL) seemed to show greater improvements in EFD with testosterone administration than with placebo (15) .
Several explanations are possible. Testosterone levels increased by approximately 3.47 nmol/L (100 ng/dL) during the sildenafil run-in period alone. The mechanisms by which sildenafil administration may increase testosterone levels are poorly understood; sildenafil has been reported to activate steroidogenic acute regulatory protein and protein kinase G1 in male rats (48 -50) . Sildenafil may have increased testosterone levels higher than the upper limit of the dose-response relationship of testosterone for erectile function (51) . Testosterone and sildenafil may share common mechanistic pathways; the optimized dose of sildenafil may have maximally induced these pathways such that no further induction could be expected from addition of testosterone. Indeed, administration of an optimized dose of sildenafil alone was associated with remarkable improvements in EFD and other sexual function domains. A high proportion of participants had diabetes, hypertension, and other comorbid conditions that may have limited erectile response; this seems unlikely because these participants re- sponded robustly to sildenafil administration with the expected improvements in erectile function. The 14-week duration may not have been sufficient to demonstrate the effects of testosterone administration; however, this seems unlikely because in most testosterone trials in men with hypogonadism, significant improvements in sexual function have been noted within 4 to 14 weeks. Regardless, the addition of testosterone to an optimized dose of sildenafil conferred no additional benefit in erectile function over placebo.
The results of this trial should not be extrapolated to imply that testosterone has no beneficial effect in men with ED who have low testosterone levels. Testosterone is an approved drug for the treatment of hypogonadism in men and may have other beneficial effects on body composition, muscle strength, physical performance, cognition, and metabolism, which were not investigated in this trial. It is also possible that testosterone administration alone may improve 1 or more domains of sexual function, including erectile function, in men with ED and low testosterone levels; this issue was also not addressed in this trial. However, our results do not support the routine addition of testosterone therapy for improving erectile response to selective PDE5 inhibitors in men with ED who have low testosterone levels, which has become commonplace in clinical practice. The day of randomization was designated as day 0. The shaded areas represent the sildenafil dose-optimization phase (weeks Ϫ7 to 0). 
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The day of randomization was designated as day 0. The shaded areas represent the sildenafil dose-optimization phase (weeks Ϫ7 to 0). Higher MSHQ scores suggest improved sexual function. MSHQ ϭ Male Sexual Health Questionnaire.
